SEARCH

SEARCH BY CITATION

References

  • Alexis, J.B., Martinez, A.E., and Lutzky, J. (2005). An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 15, 283285.
  • Antonescu, C.R., Busam, K.J., Francone, T.D., et al. (2007). L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121, 257264.
  • Ashida, A., Takata, M., Murata, H., Kido, K., and Saida, T. (2009). Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer 124, 862868.
  • Beadling, C., Jackobson-Dunlop, E, Hodi, F.S., et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 68216828.
  • Cohen, C., Zavala-Pompa, A., Sequeira, J.H., Shoji, M., Sexton, D.G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J.L. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 37283733.
  • Corless, C.L., Fletcher, J.A., and Heinrich, M.C. (2004). Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22, 38133825.
  • Curtin, J.A., Fridlyand, J., Kageshita, T., et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 21352147.
  • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 43404346.
  • Dhawan, P., Singh, A.B., Ellis, D.L., and Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62, 73357342.
  • Frost, M.J., Ferrao, P.T., Hughes, T.P., and Ashman, L.K. (2002). Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. 1, 11151124.
  • Grabbe, J., Welker, P., Dippel, E., and Czarnetzki, B.M. (1994). Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch. Dermatol. Res. 287, 7884.
  • Guo, T., Agaram, N.P., Wong, G.C., et al. (2007). Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin. Cancer Res. 13, 48744881.
  • Heinrich, M.C. et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 43424349.
  • Hodi, F.S., Friedlander, P., Corless, C.L., et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 26, 20462051.
  • Jiang, X., Zhou, J., Yuen, N.K., Corless, C.L., Heinrich, M.C., Fletcher, J.A., Demetri, G.D., Widlund, H.R., Fisher, D.E., and Hodi, F.S. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 77267732.
  • Kim, K.B., Eton, O., Davis, D.W., et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99, 734740.
  • Landi, M.T., Bauer, J., Pfeiffer, R.M., Elder, D.E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P.A., Pinkel, D., and Bastian, B.C. (2006). MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313, 521522.
  • Liu, W., Kelly, J.W., Trivett, M., et al. (2007). Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J. Invest. Dermatol. 127, 900905.
  • Longley, B.J. Jr, Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D., and Ma, Y. (1999). Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA 96, 16091614.
  • Lutzky, J., Bauer, J., and Bastian, B.C. (2008). Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 21, 492493.
  • Ma, Y., Zeng, S., Metcalfe, D.D., Akin, C., Dimitrijevic, S., Butterfield, J.H., McMahon, G., and Longley, B.J. (2002). The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99, 17411744.
  • Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K., Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian, B.C. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 95, 18781890.
  • Nishikawa, S., Kusakabe, M., Yoshinaga, K., Ogawa, M., Hayashi, S., Kunisada, T., Era, T., and Sakakura, T. (1991). In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J. 10, 21112118.
  • Taylor, M.L., and Metcalfe, D.D. (2000). Kit signal transduction. Hematol. Oncol. Clin. North Am. 14, 517535.
  • Thomas, N.E. (2006). BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 16, 97103.
  • Ugurel, S., Hildenbrand, R., Zimpfer, A. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92, 13981405.
  • Vollmer, R.T. (2007). Solar elastosis in cutaneous melanoma. Am. J. Clin. Pathol. 128, 260264.
  • Wyman, K., Atkins, M.B., Prieto, V., Eton, O., McDermott, D.F., Hubbard, F., Byrnes, C., Sanders, K., and Sosman, J.A. (2006). Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 20052011.